AURA - Aura Biosciences, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$17.00
DETAILS
HIGH:
$17.00
LOW:
$17.00
MEDIAN:
$17.00
CONSENSUS:
$17.00
UPSIDE:
143.20%
About Aura Biosciences, Inc. (https://www.aurabiosciences.com)
Headquartered in Cambridge, Massachusetts, Aura Biosciences, Inc. is a biotechnology firm established in 2009 that specializes in pioneering cancer treatments. The company leverages its proprietary virus-like drug conjugate (VDC) technology platform to address tumors with significant unmet medical needs, specifically in ocular (eye) and urologic oncology. Its flagship therapeutic candidate, AU-011, is a VDC currently in development for the treatment of primary choroidal melanoma. Furthermore, Aura Biosciences is investigating AU-011's potential for other ocular oncology applications, such as choroidal metastases.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Jill Hopkins | Chief Medical Officer & President of Research and Development | 1965 | $792,750 USD |
| Conor Kilroy | Chief Legal Officer & Secretary | 1982 | $611,162 USD |
| Anthony S. Gibney | Chief Financial & Business Officer | 1971 | $604,091 USD |
| Amy Elazzouzi | Interim Principal Accounting Officer, Senior Vice President of Finance & Treasurer | 1974 | – |
| Anthony Daniels | Vice President & Therapeutic Area of Head Ocular Oncology | – | – |
| Joe McQuaid | VP & Therapeutic Area Head of Urologic Oncology | – | – |
| Mark Plavsic | Chief Technology Officer | 1961 | – |
| Natalie C. Holles | President, CEO & Director | 1973 | – |
| Patrick Nealon | Senior Vice President of Clinical Development Operations | – | – |